Non-viral chimeric antigen receptor (CAR) T cells going viral
Immuno-Oncology and Technology · 2023-06 · 18 · 100375
DOI: 10.1016/j.iotech.2023.100375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immuno-Oncology and Technology, 2023-06. Verfasst von H Balke-Want und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, National Cancer Institute.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has made significant strides in the treatment of B-cell malignancies, but its application in treating solid tumors still poses significant challenges. Particularly, the widespread use of viral vectors to deliver CAR transgenes into T cells comes with limitations, including high costs and regulatory restrictions, which hinder the translation of novel genetic engineering concepts into clinical applications. Non-viral methods, such as transposon/transposase and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas systems, offer promising alternatives for stable transgene insertion in CAR-T cells. These methods offer the potential to increase accessibility and efficiency in the development and delivery of CAR-T cell therapies. The main challenge in using non-viral methods, however, is their low knock-in efficiency, which leads to low transgene expression levels. In this review, we discuss recent developments in non-viral approaches for CAR-T cell production, the manufacturing requirements for clinical-grade production of non-viral CAR-T cells, and the adjustments needed in quality control for proper characterization of genomic features and evaluation of potential genotoxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA.
- USC/CHLA Cell Therapy Program, University of Southern California, and Children's Hospital Los Angeles, Los Angeles, USA.
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA.
Förderung
- Deutsche Forschungsgemeinschaft
- National Cancer Institute
Zitieren
APA
Balke-Want, H., Keerthi, V., Cadinanos-Garai, A., Fowler, C., Gkitsas, N., Brown, A. K., Tunuguntla, R., Abou-El-Enein, M., & Feldman, S. A. (2023). Non-viral chimeric antigen receptor (CAR) T cells going viral. Immuno-Oncology and Technology, 18, 100375. https://doi.org/10.1016/j.iotech.2023.100375
Vancouver
Balke-Want H, Keerthi V, Cadinanos-Garai A, Fowler C, Gkitsas N, Brown AK, et al. Non-viral chimeric antigen receptor (CAR) T cells going viral. Immuno-Oncology and Technology. 2023;18:100375. doi:10.1016/j.iotech.2023.100375
BibTeX
@article{BalkeWant2023,
author = {Balke-Want, H and Keerthi, V and Cadinanos-Garai, A and Fowler, C and Gkitsas, N and Brown, A K and Tunuguntla, R and Abou-El-Enein, M and Feldman, S A},
title = {Non-viral chimeric antigen receptor (CAR) T cells going viral},
journal = {Immuno-Oncology and Technology},
year = {2023},
volume = {18},
pages = {100375},
doi = {10.1016/j.iotech.2023.100375}
}
EUVIMED